#Current affairs December 2021 PDF

[chakriralo]

প্রফেসরস কারেন্ট অ্যাফেয়ার্স সালতামামি

প্রফেসরস কারেন্ট অ্যাফেয়ার্স সালতামামি

প্রফেসরস কারেন্ট অ্যাফেয়ার্স সালতামামি ২০২১-২০২২। প্রফেসরস কারেন্ট অ্যাফেয়ার্স সালতামামি বাংলাদেশের খুব জনপ্রিয় মাসিক ম্যাগাজিন। কারেন্ট অ্যাফেয়ার্স প্রতি মাসে ঘটে যাওয়া সব খবর এই কারেন্ট অ্যাফেয়ার্স আন্তরভূক্ত থেকে এবং ভর্তি পরীক্ষার্থীদের কাছে খুব জনপ্রিয়। দেশ বিদেশের সকল মাসিক আপডেট একটি বইয়েই পাওয়া যায় ৷ কারেন্ট অ্যাফেয়ার্স এর বিভিন্ন রকমের তথ্য পাওয়া যায় যেমন বাংলাদেশ ও…

[elenajohansenauthor]

COVER REVEAL and RELEASE ANNOUNCEMENT for

FIFTY-FIVE DAYS!

December 16th, 2020!

It was supposed to be a fling.

After events beyond her control upend the course of Amber's career, she decides never to return to the band she helped found, Not My Best Day. She's done with the rock-star life, the highs of performing weighed down by the lows of grueling schedules, endless travel, and the uncomfortable intimacy of living two feet from everyone else on the bus.

But when her replacement has to bail a week before the new tour starts, the band asks her to fill in temporarily. What else can she do? They’re still family.

Rob, as the other new member in their revamped lineup, is doing his best to fit in. His time with Not My Best Day has been defined as much by Amber's absence as his presence. When she returns in their time of need, he sees what the others don’t-–how much it’s costing her to save them from disaster. When his supportiveness becomes attraction, and mutual attraction becomes a fling, Rob faces decisions he never expected. He may doubt their secret affair is good for the band, or even for himself, but he’s certain it’s what's best for her.

But what becomes of them when the tour is over? Can they really go their separate ways like nothing ever happened?

The details:

Digital pre-ordering will be available soon from multiple retailers: the book is currently “in review” everywhere, so I’ll update when it gets through the system.

Paperbacks will be available through Amazon, and there is no pre-order mechanism for that, sadly. In the meantime...

I NEED REVIEWERS! WANT AN ADVANCE REVIEW COPY? KEEP READING!

What you’re committing to: in exchange for a free copy of 55D, you will read it and post an honest review on Amazon (definitely,) Goodreads and/or Storygraph (if you use them,) and your book review blog (if you have one) within a reasonable time frame--since I’m only sending these out a week before release, rather than months ahead as a big publisher can, let’s say the end of January 2021. That’s a month and a half, plenty of time.

How to make that happen: DM me your email address, which I will not share or use for any other purpose, and also your preferred ebook format (mobi, epub, or pdf.) I’ll send you a copy as quick as I can!

[gov-info]

The U.S. Food and Drug Administration (FDA) has authorized for emergency use Coronavirus Disease 2019 (COVID-19) vaccines sponsored by Pfizer/BioNTech and Moderna. Several other COVID-19 vaccines are currently in clinical trials; additional vaccines may become available within months.

Operation Warp Speed (OWS)—the COVID-19 medical countermeasure initiative led by the Department of Health and Human Services (HHS) and the Department of Defense (DOD)—has contracted with manufacturers to purchase hundreds of millions of doses (including Pfizer/BioNTech and Moderna’s vaccines) and related supplies. OWS is also planning and implementing a nationwide vaccine program.

OWS has thus far been financed largely by emergency funding provided in the coronavirus supplemental appropriations acts. In the FY2020 laws, not much was appropriated specifically for COVID-19 vaccine- related efforts; instead, several accounts have funding available for relevant activities. In FY2021, Division M of P.L. 116-260 includes emergency appropriations directed for vaccine-specific activities.

Much of the HHS supplemental funding is available for multiple years or until expended. In addition, HHS transfer authorities in the laws allow for transfers between funds in certain HHS accounts. This Insight provides overviews of supplemental appropriations for selected vaccine-related activities and available information on allocations and obligations. It does not address health care financing issues related to vaccine administration or regular appropriations.

VACCINE RESEARCH AND DEVELOPMENT, MANUFACTURING, AND PURCHASE

COVID-19 vaccine research and development (R&D), manufacturing, and purchasing efforts are largely supported by OWS, a collaboration among several federal agencies, including the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA), DOD, and others. Some vaccine R&D is supported by NIH, BARDA, and DOD separately from the OWS efforts.

Appropriations

FY2020. In two of the four FY2020 coronavirus supplemental appropriations acts (P.L. 116-123 and P.L. 116-136), funding was made available for vaccine-related efforts to accounts at NIH, DOD, and the Public Health and Social Services Emergency Fund (PHSSEF). (PHSSEF, the parent account for BARDA, is an account for the HHS Secretary that funds additional emergency preparedness and response activities and is regularly used for one-time and pass-through funding to address public health emergencies.) In particular, up to roughly $30 billion (accounting for set-asides and transfers) in the PHSSEF account is available for vaccine development, manufacturing, and purchase until September 30, 2024. These funds are also designated for other emergency response activities, such as medical supply procurement for the Strategic National Stockpile, supporting health care surge response, and the development, purchase, and manufacturing of therapeutics and diagnostics.

FY2021. Division M of P.L. 116-260 appropriates $22.945 billion to the PHSSEF account to be available for similar purposes as described above until September 30, 2024. Of the total, $19.695 billion is available to BARDA for “necessary expenses of manufacturing, production, and purchase ... of vaccines, therapeutics, and ancillary supplies.” The law directs the HHS Secretary to “purchase vaccines developed using funds made available ... to respond to an outbreak or pandemic related to coronavirus in quantities determined by the Secretary to be adequate to address the public health need.” Funds may reimburse obligations for vaccines and therapeutics “planning, development, preparation, and purchase” incurred prior to enactment.

Supplemental appropriations to NIH Office of the Director account could also be used, in part, for vaccine-related R&D.

Allocations, Obligations, and Reporting

According to a Government Accountability Office (GAO) report published on November 30, as of October 31, 2020, HHS had allocated about $13.8 billion in coronavirus supplemental funding for “vaccines”—including $150 million in NIH allocations and the rest in BARDA allocations. Of this allocated amount, about $13.3 billion had been obligated and $1.28 billion had been expended.

The report also states that DOD has allocated about $1.64 billion in funding from the CARES Act (P.L. 116-136) toward a medical countermeasures development portfolio. DOD has five COVID-19 vaccine development projects underway.

According to a separate November GAO report, as of October 15, OWS had announced contract awards to support six vaccines, with obligations totaling at least $10 billion and a total estimated value of at least $18 billion, with awards made by both DOD and BARDA.

P.L. 116-260 adds a reporting requirement on OWS funding that includes total obligations and funding awards exceeding $20 million by department/agency and appropriations act, to be provided not later than 30 days after enactment, and regularly updated thereafter, to the House and Senate Appropriations committees.

VACCINE DEPLOYMENT AND DISTRIBUTION

As a part of OWS, CDC has been working with state, local, tribal, and territorial (SLTT) jurisdictions to plan and implement a nationwide vaccination program.

Appropriations:

FY2020. In two COVID-19 supplemental appropriations acts (P.L. 116-123 and P.L. 116-136), CDC received a total of $6.5 billion (of which $800 million is designated global funding). Much of this funding is available broadly “to prevent, prepare for, and respond to coronavirus, domestically and internationally.”

FY2021. Division M of P.L. 116-260 appropriates $8.75 billion to CDC, for “activities to plan, prepare for, promote, distribute, administer, monitor, and track coronavirus vaccines to ensure broad-based distribution, access, and vaccine coverage,” to be available until September 30, 2024. Of this total, $4.5 billion is for SLTT grants (or cooperative agreements), of which $210 million is to be transferred to the Indian Health Service (IHS) for tribes and tribal organizations and a separate amount of not less than $300 million is for “high-risk and underserved populations, including racial and ethnic minority populations and rural communities.” At least $1 billion in SLTT grants must be made available within 21 days, and funds can reimburse obligations incurred prior to enactment. PHSSEF appropriations described above may also be relevant.

 Allocations, Obligations, and Reporting

To date, CRS could not identify an exact amount of related allocations and obligations. Funding announcements include the following:

a contract to a company, McKesson, to manage the nationwide distribution;

a partnership with commercial pharmacies for providing vaccines to long-term care facilities;

SLTT grants under an existing immunization cooperative agreement—announced in September and December—and other smaller demonstration grants; and the first $3 billion in SLTT grants from P.L. 116-260 is to be provided by January 19, 2021.

DOD has assisted with logistics planning. Other agencies manage vaccine distribution efforts among their employees and covered populations (e.g., IHS and the Department of Veterans Affairs [VA]), incollaboration with the nationwide effort.

P.L. 116-260 adds a requirement that CDC “provide an updated and comprehensive coronavirus vaccine distribution strategy and a spend plan, to include funds already allocated for distribution” to specified congressional committees within 30 days.

[ambitiousbaba]

December 2021 Current Affairs PDFs Different Formats: ambitiousbaba.com (AB)

December 2021 Current Affairs PDFs Different Formats Current affairs play a crucial role in all competitive exams. Aspirants who are appearing for these exams must be well prepared in current affairs. Ambitiousbaba provides monthly Current affairs PDF in three formats: The Hindu Review(Bilingual) , Best 200+ Current affairs MCQ(Bilingual) and One-liners current affairs. We provide One-liners…

[educationstudyiq]

Daily Current Affairs

Today our teachers focus on international affairs topics, Which is a very important topic in current affairs so visit the site and get current affairs of date 31st December 2021 and also users get a free pdf of the pdf. To know more visit the site:- Current affairs

[sosation]

To My Colleagues: (An unsent letter to High School teachers during a pandemic)

April 2021

To my colleagues,

In regards to the current state of affairs with our student population, their grades and their mental health, I think there are a few things we should consider when it comes to putting in their final grade for the year:

1.This year has been hard for everyone.

The fact that we are going through a global pandemic is no fault of our students. They are doing the best they can, just like the rest of us- some better than others. If you looked at Mrs. B****'s email regarding the testimonies of students and families and what they have been dealing with you will understand that deaths in the family, loss of employment for the primary earner and the need to take in or take care of extended family members are very common things our students are dealing with. As a result many, many of our students are babysitting all day or primary caregiving for their grandparents and/or have had to pick up menial jobs to help the family make ends meet. Others are out on their own working full time and paying rent--and somehow, thankfully, still trying to stay in school. Obviously, this contributes to increased anxiety and depression. Many of our students have either attempted suicide or were/are hospitalized due to suicidal ideations. Anyone who has ever had to deal with strife at home knows that family comes first, even over education. I know all of you are aware of Maslow’s Hierarchy of Needs. Food, water, shelter, and sleep are all on the bottom tier -- the most important-- followed by personal security, employment, health, and resources on the next tier. So, from a lot of our students’ perspectives, our class just isn’t the most important thing in their lives right now-- nor should it be. “Love and Belonging” is the third tier. How can we tell our students that they are loved and that they belong more than by showing them grace and passing them?

2. Understand your power and your role in the system and in your students' lives.

We have the power and the ability to affect the course of these students’ lives with the decisions we make in regards to passing or failing. Research shows that failing students, and students who were held back, are more likely to drop out. There is no evidence that shows punitive grading-- punishing students with grades as a means to motivate them-- works. On the contrary, it makes students feel like they can’t cut it and increases the chances of them dropping out. Failing your students in no way helps anyone. It can ruin the lives of students because they may never graduate due to perceived ineptitude. Our community is the one that suffers when students drop out. They have a hard time finding a job and getting into higher education and can end up homeless. Youth homelessness is on the rise and us failing students will only contribute to that statistic. So we have the power to show grace-- and provide an opportunity for someone that could uplift them in the future, or show malice or disregard and punish a student when they are having to choose between their family, their well-being, or their education and not choosing the latter.

If we choose to fail our students due to perceived apathy, or because they “aren’t putting in the effort,” or as a way to get back at them for “getting away with doing nothing,” then we are not just choosing to be petty, we are choosing to allow that student to potentially have a harder life because of it. We have that power. Does anyone deserve to have their future jeopardized because of a petty teacher? We must ask ourselves “Does public education exist to ruin lives?” No. Then why do that with it-- even if the system allows it?

The other path that we can choose to take is to care for our students--the ones who we are hired to care for-- and provide them with opportunities that could enrich their lives and, more importantly, provide things like second or third chances. Just about everyone has a story about someone who showed them unmerited grace and how it changed their life. We have the opportunity to provide that story for our students. Or we can put them on the path of a very different story, one that isn’t as positive and one that maybe ends in the street. That is the choice we have to make.

3. Remember that “learning” and “education” are two different things. Emphasize the former over the latter.

Grades do not reflect learning. We all inherently know this. And when you go back to the mid-late 1800’s to see why they were created in the first place you find that it is not even what they were designed to measure.

When we make students do a bunch of mindless busy work in order to put a number in the gradebook they are not learning anything other than that they need to do X to get a 100. They are taught to work for the grade, not to learn. We should be incentivizing them to actually learn, not just “do this specific order of operations because you need the grade.” When we auction off grades to students: “Please if anyone turns in the assignment- even though it was due 3 weeks ago-- I’ll still give you a 90,” what we are teaching them is that grades are meaningless. How do we deal with this? Be honest with ourselves and your students about what grades actually mean and reflect and don’t fool ourselves into thinking that they reflect some objective truth about a students ability. They don’t and they never did. When we accept this, it becomes clear how arbitrary the 69-70 pass/fail distinction really is.

4. The world is not a meritocracy.

Life is unfair. We say it all the time and it is true. So why, then, do we treat our students' grades as some sort of fair arbiter. “It’s not fair to the other students if I pass so-and-so...” implies that grades are inherently fair, which we have already established they are not. Every teacher grades vastly differently and an A in English at one school may not be an A at another. Additionally, students learn at wildly varying rates. Some 9th graders read at a 12th grade level and some read at a 5th grade level, and this goes for every student in every grade. We all know this. This is why we are supposed to differentiate our assignments, because of this inherent inequality in human abilities. If every teacher appropriately differentiated the difficulty of our assignments to the correct subset of appropriately capable students, then every student would pass. However, rather than doing this, most of us put the responsibility off on the students.

The real world is not fair, so we shouldn’t pretend that grades are. When we come to realize this, we realize that it simply comes down to one thing: our decision--our power in this situation. Traditionally, we have put the responsibility off on the students and in doing so, abdicated our own in the process. Realize that actually we are responsible for the students' outcomes after high-school. We have the power to decide whether they pass or fail--which will have long term impacts on their future. We can tell ourselves it is their responsibility but we are the ones who sign off on the grade verifications, not them. We ultimately decide their fate. So if we tell ourselves, “they did this to themselves” then we are lying to ourselves. We, alone, have the choice. I urge you to choose wisely, for their sake.

So to recap, our students are dealing with unimaginable situations and stress. You have a role in this system and a role in your students lives, which role will you emphasize? Grades do not equal learning. Use taxpayer money wisely and lastly, life isn’t fair and neither is grading- so let’s not pretend that it is. With all these in mind and the understanding that we have the ultimate power in this situation, I hope we can all see that the lives and the futures of our students depend on US and the decisions WE make. Thank you for your time.

Sincerely,

Anthony Sosa

****** High School

U.S. History

*201

M.Ed. Curriculum and Instruction

B.A. History

"The past is never dead. It's not even past." - William Faulkner

P.S.

If any of the things I’ve said or the perspectives I have presented are new to you, or if you would like to know more about any of these things I do have reading recommendations:

Mrs. B***** Doc of Testimonies:

**********

Books:

Ungrading: Why Rating Students Undermines Learning (and What to Do Instead) By Susan D Blum (Teaching and Learning in Higher Education) Paperback – December 1, 2020

https://www.amazon.com/Ungrading-Students-Undermines-Learning-Education/dp/1949199827

Hacking Assessment: 10 Ways To Go Gradeless In a Traditional Grades School by Starr Sackstein by «Dr. Doug Green

https://www.drdouggreen.com/2016/hacking-assessment-10-ways-to-go-gradeless-in-a-traditional-grades-school-by-starr-sackstein/

Grades and Grading Practices (Obstacles to Improving Education and to Helping - At-Risk Students) Charles H. Hargis (2003)

--contact me if you would like a copy of the PDF

Articles:

Liberating Grades/Liberatory Assessment by SJ Miller

http://www.sjmiller.info/uploads/8/8/5/4/88548862/lib_grades.pdf

Competitive Grading Sabotages Good Teaching BY JOHN D. KRUMBOLTZ AND CHRISTINE J. YEH

http://cultureofpeace.ernestojunsantos.com/uploads/6/4/8/7/6487837/competitive_grading_sabotages_good_teaching.pdf

The Relations of Learning and Grade Orientations to Academic Performance Hall P. Beck, Sherry Rorrer-Woody, and Linda G. Pierce

https://libres.uncg.edu/ir/asu/f/Beck_Hall_1991_The_Relations_of_Learning.pdf

Human Restoration Project Resources:

https://www.humanrestorationproject.org/research?categories=ungrading

[jobscirculars]

January Current Affairs PDF 2021-2022

January Current Affairs PDF 2021-2022

January Current Affairs PDF Download  2021-2022 has been published at jobscirculars.com. Download Current Affairs 2021 is most important your job exam. Professors Current Affairs 2021 All Month Download is available on our website. You can find full details about Current Affairs 2021 All Month Download. You can get their Current Affairs 2021 All Month Download from our website and our Social…

[ambitiousbaba]

The Hindu Review Monthly Current Affairs PDF : December 2021 Bilingual

The Hindu Review Monthly Current Affairs PDF : December 2021 Bilingual

The Hindu Review Monthly Current Affairs PDF  The Hindu Review December 2021 : Here we are launching The Hindu Review December 2021 PDF in Bilingual (Hindi+English) for an effective revision of the current affairs. As we all know Current Affairs Sections are asked from the previous 5-6 months in Every Competitive exams like IBPS PO Mains, SBI PO Mains, IBPS Clerk Mains, IBPS RRB PO Mains, IBPS…

[athiranair23]

Kidney Cancer Drugs Market Analysis (2020-2027)

Renal cell carcinoma (RCC) is one of the most common types of kidney cancer in adults. At the advanced progression stage of kidney cancer, where removal of the cancerous cells is vital; surgical removal of kidney are performed to get cure from the disease. This treatment method was later replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.

In recent times, owing to increasing drug resistivity key players are shifting its focus in developing combination drug therapy for kidney cancer medication. Increasing trend of combination drug therapy in near future, will help in overcoming potential hazards of drug resistivity and offer treatment option in renal cell carcinoma.

In addition, key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, F. Hoffmann-La Roche Ltd. is working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) — an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion— which will be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is currently in phase III stage, which is expected to be launched in the market by the end of 2021.       

Market Dynamics

Key drug manufacturers in the kidney cancer drugs market are adopting in-organic growth strategies to collaborate with other drug manufacturers and develop renal cell carcinoma drugs.

For instance, in March 2018, Eisai Co., Ltd. and Merck & Co., Inc. entered into strategic collaboration agreement for co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor, for renal cell carcinoma. Under the terms of agreement, Eisai and Merck will develop and commercialize LENVIMA jointly, both as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab). 

Moreover, in June 2016, Eisai Co., Ltd. entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and medical affairs activities on a combination treatment for advanced renal cell carcinoma. According to the agreement, sales teams from both pharmaceutical companies will promote the availability of Levinima (lenvatinib mesylate) to healthcare professionals in the U.S.��     

In December 2013, Cancer Research UK and Cancer Research Technology, signed an agreement with AstraZeneca to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat kidney cancer.   

Key features of the study:

·         This report provides in-depth analysis of kidney cancer drugs market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2018, as the base year.

·         It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

·         This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategy adopted by key players

·         It profiles key players in the global kidney cancer drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies.

·         Key companies covered as a part of this study include, Pfizer Inc., Novartis International AG, Genentech, Inc.,  Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd. and Exelixis, Inc.

·         Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type upgradation, market expansion, and marketing tactics

·         The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, researchers, kidney cancer drug manufacturers, new entrants, and financial analysts.

·         Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the kidney cancer drugs market.

Detailed Segmentation:

·         Global Kidney Cancer Drugs Market, By Therapy:

o    Targeted Therapy

o    Immunotherapy

o    Chemotherapy

·         Global Kidney Cancer Drugs Market, By Pharmacological Class:

o    Angiogenesis Inhibitors

o    mTOR Inhibitors

o    Cytokines

o    Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)

·         Global Kidney Cancer Drugs Market, By Distribution Channel:

o    Hospital Pharmacy

o    Retail Pharmacy   

o    Online Pharmacy 

·         Global Kidney Cancer Drugs Market, By Geography:

o    North America

§  By Country:

§  U.S.

§  Canada

§  By Therapy:

§  Targeted Therapy

§  Immunotherapy

§  Chemotherapy

§  By Pharmacological Class:

§  Angiogenesis Inhibitors

§  mTOR Inhibitors

§  Cytokines

§  Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)

§  By Distribution Channel:

§  Hospital Pharmacy

§  Retail Pharmacy   

§  Online Pharmacy

o    Europe

§  By Country:

§  U.K.

§  Germany

§  Italy

§  Spain

§  France

§  Russia

§  Rest of Europe

§  By Therapy:

§  Targeted Therapy

§  Immunotherapy

§  Chemotherapy

§  By Pharmacological Class:

§  Angiogenesis Inhibitors

§  mTOR Inhibitors

§  Cytokines

§  Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)

§  By Distribution Channel:

§  Hospital Pharmacy

§  Retail Pharmacy   

§  Online Pharmacy

o    Asia Pacific

§  By Country:

§  China

§  India

§  Japan

§  ASEAN

§  Australia

§  South Korea

§  Rest of Asia Pacific

§  By Therapy:

§  Targeted Therapy

§  Immunotherapy

§  Chemotherapy

§  By Pharmacological Class:

§  Angiogenesis Inhibitors

§  mTOR Inhibitors

§  Cytokines

§  Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)

§  By Distribution Channel:

§  Hospital Pharmacy

§  Retail Pharmacy   

§  Online Pharmacy

o    Latin America

§  By Country:

§  Brazil

§  Mexico

§  Argentina

§  Rest of Latin America

§  By Therapy:

§  Targeted Therapy

§  Immunotherapy

§  Chemotherapy

§  By Pharmacological Class:

§  Angiogenesis Inhibitors

§  mTOR Inhibitors

§  Cytokines

§  Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)

§  By Distribution Channel:

§  Hospital Pharmacy

§  Retail Pharmacy   

§  Online Pharmacy

o    Middle East

§  By Country:

§  GCC

§  Israel

§  Rest of Middle East

§  By Therapy:

§  Targeted Therapy

§  Immunotherapy

§  Chemotherapy

§  By Pharmacological Class:

§  Angiogenesis Inhibitors

§  mTOR Inhibitors

§  Cytokines

§  Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)

§  By Distribution Channel:

§  Hospital Pharmacy

§  Retail Pharmacy   

§  Online Pharmacy

o    Africa

§  By Country:

§  North Africa

§  Central Africa

§  South Africa

§  By Therapy:

§  Targeted Therapy

§  Immunotherapy

§  Chemotherapy

§  By Pharmacological Class:

§  Angiogenesis Inhibitors

§  mTOR Inhibitors

§  Cytokines

§  Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)

§  By Distribution Channel:

§  Hospital Pharmacy

§  Retail Pharmacy   

§  Online Pharmacy

·         Company Profiles

o    Pfizer Inc.*

§  Company Overview

§  Product Portfolio

§  Financial Performance

§  Key Strategies

§  Recent Developments

o    Novartis International AG

o    Genentech, Inc.

o    Active Biotech AB

o    Amgen Inc.

o    Bayer AG

o    Cipla Limited

o    Hoffmann-La Roche AG

o    Bristol-Myers Squibb Company

o    Eisai Co., Ltd.

o    Exelixis, Inc.

  Request sample copy here :  

https://www.coherentmarketinsights.com/insight/request-sample/2399

Request PDF brochure here:        

https://www.coherentmarketinsights.com/insight/request-pdf/2399

Click here to buy: https://www.coherentmarketinsights.com/insight/buy-now/2399

CMI Services: https://www.coherentmarketinsights.com/services

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

·        Customized Market Research Services

·        Industry Analysis Services

·        Business Consulting Services

·        Market Intelligence Services

·        Long term Engagement Model

·        Country Specific Analysis

Contact Us:   

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email : sales@coherentmarketinsights.com

 Reference/Source: https://www.coherentmarketinsights.com/market-insight/kidney-cancer-drugs-market-2399

[tecnovaconsultingfirmindia]

An Outlook on the Textile Industry in India- Present and Future Prospects of Growth for Global Giants

India is the world’s second largest producer of textiles and garments and the world’s third largest producer of cotton after China and the USA. The Indian market is also the second largest in terms of consumption of Cotton, after China.  

One of the oldest and the largest textile industries in the world, the Indian textile industry is currently estimated at US$150 Billion as of December 2018 and is expected to reach US$ 250 Billion by the year 2019. The Indian textiles industry, carrying hand-spun and hand-woven textile sectors at one end of the spectrum and capital-intensive sophisticated mills sector at another end of the spectrum, is extremely vast and varied. The Indian textile industry contributed 7 percent of the Indian industry output in the year 2017-2018. Known to be the second-largest employment generating sector in the country, the Indian textile sector contributes to 2 percent of the country’s GDP and provides direct employment to more than 45 million people. The financial year 2018 took the Indian textile exports to US$ 39.20.

The growth in building and construction is expected to raise the demand for non-clothing textiles. Following factors work as the strengths of the Indian textile industry-

The remarkable increase in the income levels of the Indian population

Abundant availability of raw materials such as cotton, wool, silk, and jute result in a continuous increase in the demand in the Indian textile industry

Easy access to low cost and skilled manpower offering a competitive edge to the industry

Better assistance in terms of building market entry strategy for global organization by the management consulting firms in india

The fundamental strength of the Indian textile industry is its strong production base with a wide range of fibers and yarns. These are natural fibers such as cotton, jute, silk, wool, and synthetic and man-made fibers like polyester, viscose, nylon, and acrylic. The textile industry is capital and technology-intensive comparable with automobiles, aircraft, computers, and heavy machinery industry. Buyer-driven value chains enhance trade-led industrialization, which has become common in labor-intensive, consumer-goods industries and consumer electronics.

In comparison with other countries like China, the cost of textile production in India is quite less. Due to this, the Chinese textile manufacturers have lost the competitive advantage of lower cost of production. This, as a result, offered an opportunity to the Indian textile sector to overtake the market share of China in the developed world, especially in the European Union and the United States, both comprising of around 60 percent of the global export market.

Considering this, the Indian government took certain measures to further enhance the Indian textile industry and promote mergers and acquisitions consulting firms in india. Some of the major investments in the Indian textiles industry are as below-

100 percent Foreign Direct Investment has been allowed in the Indian Textile sector. Moreover, free trade with ASEAN is allowed in order to boost exports in the country.  

The Indian government is making huge investments under the Scheme for Integrated Textile Parks (SITP) and Technology Upgradation Fund Scheme to encourage more private equity in order to train the workforce.

The Cabinet Committee on Economic Affairs (CCEA), Government of India has approved a new skill development scheme for capacity building in the textile sector with an outlay of US$ 202.9 Million from 2017-18 to 2019-20.

The Future Group is planning to open 80 new stores under its affordable fashion format, FBB and is targeting the sales of 230 million units of garments by March 2018, This number is further expected to grow to 800 Million units by the year 2021.

Max Fashion, a part of Dubai based Landmark Group, plans to expand its sales network to 400 stores in 120 cities by investing the US $60 Million in the next 4 years.

To conclude, programs like Skill India and Make-in-India, along with continuous development and growth in the management consulting firms in India for foreign companies, is working in favor of the developments in the Indian textile industry. The access to skilled manpower and a good market for textile products, the industry is becoming competitive in the global market. With proper market entry strategy for global giants in the market, the future for the Indian textile industry looks promising, buoyed by both strong domestic consumption as well as export demand.  

Source-

https://www.ibef.org/industry/textiles.aspx

http://www.sriyadithatextile.com/home/interviews/opportunities-for-indian-textile-industry

https://crimsonpublishers.com/tteft/pdf/TTEFT.000538.pdf

Website: www.tecnovaglobal.com

[peopleintrees]

CALL FOR IDEAS by FEMALE-IDENTIFYING CREATORS – The Montreal/Miami New Narratives 3 Day Lab -DEADLINE OCT 6th 2020 @filmgatemiami

Explore the future of mixed-reality storytelling. Participate in a 3-day guided design workshop in Miami. Receive remote mentoring for your project. Present your project and your creative process to an audience of industry professionals and funders, in Miami and Montreal.

Submission deadline: October 6, 2020.

THE CONTEXT

FilmGate Miami, MUTEK, the National Film Board of Canada interactive studio, and O Cinema are organizing the Montréal/Miami New Narratives Lab, a cross-cultural exchange between creative storytellers, organizations, and innovative technology industries, in pursuit of exploring the future of storytelling in augmented and mixed reality. It is also an opportunity to combine our efforts across borders and continue the work of gender parity in the global tech industry.

Offering this opportunity to female-identifying creators, we aim to counter current industry statistics by creating an inclusive space, in which they can develop strong ideas for immersive and interactive storytelling and thrive in the creative roles that such projects demand.

WHAT ARE WE LOOKING FOR?

We invite creators from different backgrounds (such as virtual, augmented and mixed reality, data science, film, architecture, dance, literature, music, fine arts or even street art, etc.) to submit a proposal for an augmented and mixed-reality project.

We encourage the submission of ambitious ideas, combining an original narrative with a strong desire to play with the codes of interactive storytelling in a mixed-reality experience. We are looking for non-fiction projects with an original worldview.

THE PROCESS

Selected for their meaningful proposals, six creators, three from Miami and three from Montreal, will engage in a creative process from February to December 2021. Throughout the Lab, they will work together on their project ideas and receive mentorship and hands-on support from expert storytellers and technologists.

If the health measures related to the pandemic allow it, the 3-day Lab in Miami* will result in several original mixed-reality narrative concepts, supported by proof of concept material.

In the months following the workshop, between March and December 2021, the creators will receive mentorship to help them prepare a presentation on their concept. In the final stage, creators will present their concepts and creative process at the FilmGate Miami Interactive Media Festival in December 2021.

Selected creators will receive $ 1,500 (US) for their participation.

For all the details, please consult the call for ideas PDF document.

 *Depending on the evolution of the health crisis, the lab could be adapted to take place 100% online or be postponed to a later date.

The Montréal/Miami New Narratives Lab is organized by FilmGate Miami, MUTEK, the National Film Board of Canada and O Cinema, in collaboration with the Société de développement des entreprises culturelles (SODEC), with the support of the Conseil des arts et des lettres du Québec and the Miami-Dade County Department of Cultural Affairs.

[ambitiousbaba]

Best 200+ Current Affairs MCQ’s December 2021 (Bilingual) : Download PDF

Best 200+ Current Affairs MCQ’s December 2021 (Bilingual) : Download PDF

200+ Current Affairs PDF December 2021  ‘Current Affairs MCQ PDF December 2021’ : As IBPS PO, SBI Clerk, SBI PO, IBPS RRB , IBPS Clerk ,& Other Exams upcoming in few Days, so here our expert team provide you ‘Best 200+ Current Affairs MCQ PDF’ for the month of December 2021. The General Awareness Section of Banking Exams covers Current Affairs 2021. Most of the questions in GA Sections appear…

[ambitiousbaba]

Weekly MCQ Current Affairs PDF : 19th December 2021 to 1st January 2022

Weekly MCQ Current Affairs PDF : 19th December 2021 to 1st January 2022

Weekly MCQ Current Affairs PDF: December Part 3 & 4 In today’s exams, whether they be SBI PO, SBI Clerk, IBPS PO, IBPS Clerk, LIC, SSC, Railway, or other government exams, general awareness or current affairs plays a key role. We’ve produced a PDF of weekly MCQ Current Affairs for future government examinations that includes a General Knowledge part, knowing the importance of Current Affairs or…

[ambitiousbaba]

One Liner Current Affairs PDF : December 2021

One Liner Current Affairs PDF : December 2021

December Month One Liner Current Affairs PDF 2021 One Liner Current Affairs PDF December 2021: As we all know that all the Mains exams like SBI Clerk , IBPS PO, IBPS Clerk, RRB PO , RRB Clerk , SBI PO Mains, RBI , Para 13.2 and Other Government exams. So here we came out with Monthly One Liner Current Affairs PDF for the month of December 2021. It will help you to cope-up with the Current affairs…

[ambitiousbaba]

Weekly MCQ Current Affairs PDF : 12th December to 18th December 2021

Weekly MCQ Current Affairs PDF : 12th December to 18th December 2021

Weekly MCQ Current Affairs PDF: December Part 2 In today’s exams, whether they be SBI PO, SBI Clerk, IBPS PO, IBPS Clerk, LIC, SSC, Railway, or other government exams, general awareness or current affairs plays a key role. We’ve produced a PDF of weekly MCQ Current Affairs for future government examinations that includes a General Knowledge part, knowing the importance of Current Affairs or…